Additionally, the anti-lymphangiogenesis activity of anlotinib was further confirmed via immunofluorescence staining of 4T1 and CT26 tumor tissues, as evidenced by the decreased expression of LYVE-1 (Supplementary Fig. S2). Here, LYVE1 is linked to neoplasm.